Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults
NCT04762680Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of monovalent [B.1.351] CoV2 preS dTM-AS03 in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started Feb 2021; status: completed.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04762680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762680.